BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
17.44
-0.62 (-3.43%)
At close: Apr 28, 2026, 4:00 PM EDT
17.16
-0.28 (-1.58%)
After-hours: Apr 28, 2026, 5:53 PM EDT
BioAge Labs Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for BioAge Labs stock have an average target of 51.5, with a low estimate of 12 and a high estimate of 73. The average target predicts an increase of 195.30% from the current stock price of 17.44.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 27, 2026.
Analyst Ratings
The average analyst rating for BioAge Labs stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 3 | 3 |
| Buy | 0 | 0 | 1 | 2 | 2 | 2 |
| Hold | 2 | 3 | 2 | 2 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +186.70% | Mar 27, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $15 → $52 | Strong Buy | Maintains | $15 → $52 | +198.17% | Mar 10, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $60 | Buy | Initiates | $60 | +244.04% | Feb 25, 2026 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $9 → $62 | Hold → Strong Buy | Upgrades | $9 → $62 | +255.50% | Feb 18, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $73 | Buy | Initiates | $73 | +318.58% | Jan 27, 2026 |
Financial Forecast
Revenue This Year
73.84M
from 9.00M
Increased by 720.93%
Revenue Next Year
2.82M
from 73.84M
Decreased by -96.18%
EPS This Year
-2.65
from -2.24
EPS Next Year
-2.67
from -2.65
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 498.8M | 10.5M | ||||||
| Avg | 73.8M | 2.8M | ||||||
| Low | n/a | -2.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5,444.7% | -85.8% | ||||||
| Avg | 720.9% | -96.2% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.39 | -1.74 | ||||||
| Avg | -2.65 | -2.67 | ||||||
| Low | -3.07 | -3.63 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.